Studio osservazionale retrospettivo-prospettico italiano sull'uso di zanubrutinib in pazienti con leucemia linfatica cronica – Studio AZALEA (BGB-3111_MA-IT-401).
29 OTT 2024 | DOCUMENTO
You are now leaving the website
This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.
This link will take you to a third-party website outside of beonemedaffairs.com.
[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.
By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.
Do you want to leave beonemedaffairs.com
You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed
